120 related articles for article (PubMed ID: 31738536)
1. Cross-Protective Abilities of Hyaluronic Acid Modified with Tetraglycine-l-octaarginine as a Mucosal Adjuvant against Infection with Heterologous Influenza Viruses.
Tanishita S; Ukawa M; Tomono T; Yoshida Y; Tsujioka T; Miyata K; Tobita E; Uto T; Baba M; Sakuma S
Bioconjug Chem; 2019 Dec; 30(12):3028-3037. PubMed ID: 31738536
[TBL] [Abstract][Full Text] [Related]
2. Biodegradable Hyaluronic Acid Modified with Tetraglycine-l-octaarginine as a Safe Adjuvant for Mucosal Vaccination.
Ukawa M; Tanishita S; Yagi H; Yoshida Y; Tomono T; Shigeno K; Tobita E; Uto T; Baba M; Sakuma S
Mol Pharm; 2019 Mar; 16(3):1105-1118. PubMed ID: 30715891
[TBL] [Abstract][Full Text] [Related]
3. Cross-reactivity of immunoglobulin A secreted on the nasal mucosa in mice nasally inoculated with inactivated H1N1 influenza A viruses in the presence of D-octaarginine-linked polymers.
Sakuma S; Morimoto N; Nishida K; Murakami T; Egawa T; Endo R; Kataoka M; Yamashita S; Miyata K; Mohri K; Ochiai K; Hiwatari K; Koike S; Tobita E; Uto T; Baba M
Eur J Pharm Biopharm; 2015 May; 92():56-64. PubMed ID: 25720816
[TBL] [Abstract][Full Text] [Related]
4. Demonstration of d-Octaarginine-Linked Polymers as Promising Adjuvants for Mucosal Vaccination through Influenza Virus Challenge.
Miyata K; Mohri K; Egawa T; Endo R; Morimoto N; Ochiai K; Hiwatari K; Tsubaki K; Tobita E; Uto T; Baba M; Sakuma S
Bioconjug Chem; 2016 Aug; 27(8):1865-71. PubMed ID: 27463562
[TBL] [Abstract][Full Text] [Related]
5. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
6. Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung.
Proudfoot O; Esparon S; Tang CK; Laurie K; Barr I; Pietersz G
BMC Infect Dis; 2015 Feb; 15():101. PubMed ID: 25887952
[TBL] [Abstract][Full Text] [Related]
7. Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.
Bhide Y; Dong W; Gribonika I; Voshart D; Meijerhof T; de Vries-Idema J; Norley S; Guilfoyle K; Skeldon S; Engelhardt OG; Boon L; Christensen D; Lycke N; Huckriede A
Front Immunol; 2019; 10():646. PubMed ID: 30984200
[TBL] [Abstract][Full Text] [Related]
8. Poly I:C adjuvanted inactivated swine influenza vaccine induces heterologous protective immunity in pigs.
Thomas M; Wang Z; Sreenivasan CC; Hause BM; Gourapura J Renukaradhya ; Li F; Francis DH; Kaushik RS; Khatri M
Vaccine; 2015 Jan; 33(4):542-8. PubMed ID: 25437101
[TBL] [Abstract][Full Text] [Related]
9. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
[TBL] [Abstract][Full Text] [Related]
10. Nasal absorption enhancement of protein drugs independent to their chemical properties in the presence of hyaluronic acid modified with tetraglycine-L-octaarginine.
Tomono T; Yagi H; Ukawa M; Ishizaki S; Miwa T; Nonomura M; Igi R; Kumagai H; Miyata K; Tobita E; Kobayashi H; Sakuma S
Eur J Pharm Biopharm; 2020 Sep; 154():186-194. PubMed ID: 32681963
[TBL] [Abstract][Full Text] [Related]
11. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
12. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
[TBL] [Abstract][Full Text] [Related]
13. Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.
Wu H; Bao Y; Wang X; Zhou D; Wu W
Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28129034
[TBL] [Abstract][Full Text] [Related]
14. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
15. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
[TBL] [Abstract][Full Text] [Related]
16. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
17. Protective antibody responses against A(H1N1)pdm09 primed by infection and recalled by intranasal vaccination.
Ikeda K; Ainai A; Hasegawa H
Vaccine; 2015 Nov; 33(45):6066-9. PubMed ID: 26432916
[TBL] [Abstract][Full Text] [Related]
18. Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge.
Moriyama M; Chino S; Ichinohe T
Vaccine; 2017 Feb; 35(7):1001-1007. PubMed ID: 28111142
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous immunisation with zymosan generates mucosal IgA-eliciting memory and protects mice from heterologous influenza virus infection.
Nihei Y; Higashiyama M; Miyauchi K; Haniuda K; Suzuki Y; Kubo M; Kitamura D
Int Immunol; 2023 Aug; 35(8):377-386. PubMed ID: 37140172
[TBL] [Abstract][Full Text] [Related]
20. Protective efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the European Avian-like H1N1 swine influenza virus in mice and pigs.
Ruan BY; Wen F; Gong XQ; Liu XM; Wang Q; Yu LX; Wang SY; Zhang P; Yang HM; Shan TL; Zheng H; Zhou YJ; Tong W; Gao F; Tong GZ; Yu H
Vet Microbiol; 2018 Aug; 222():75-84. PubMed ID: 30080677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
